{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:34:59Z","timestamp":1794659699314,"version":"4.9.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clinre.2024.102377","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T18:00:54Z","timestamp":1716141654000},"page":"102377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-1883","authenticated-orcid":false,"given":"Salah Abdalrazak","family":"Alshehade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2024.102377_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-024-00051-1","article-title":"NASH field celebrates \u2018hurrah moment\u2019 with a first FDA drug approval for the liver disease","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinre.2024.102377_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120732","article-title":"The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: new insights and future directions","volume":"305","author":"Alshehade","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.clinre.2024.102377_bib0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102377_bib0004","first-page":"11","article-title":"Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments","author":"Peng","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinre.2024.102377_bib0005","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102377_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.12.029","article-title":"Prevalence of high-risk nonalcoholic steatohepatitis (NASH) in the United States: results from NHANES 2017\u20132018","volume":"21","author":"Vilar-Gomez","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2024.102377_bib0007","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clinre.2024.102377_bib0008","article-title":"Non-alcoholic steatohepatitis (NASH) and organokines: what is now and what will be in the future","volume":"23","author":"Dos Santos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2024.102377_bib0009","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102377_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.767314","article-title":"Current and potential therapies targeting inflammation in NASH","volume":"12","author":"Albhaisi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinre.2024.102377_bib0011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1201\/9781003386698-18","article-title":"Anti-infl ammatory drugs: metabolic inflammation in NASH\u2014a drug target?","author":"Armandi","year":"2023","journal-title":"Need-to-Know NAFLD Complet Guid to Nonalcoholic Fat Liver Dis"},{"key":"10.1016\/j.clinre.2024.102377_bib0012","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"TouchREVIEWS Endocrinol"},{"key":"10.1016\/j.clinre.2024.102377_bib0013","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102377_bib0014","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinre.2024.102377_bib0015","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2024.102377_bib0016","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.4254\/wjh.v13.i11.1584","article-title":"Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity","volume":"13","author":"Pal","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2024.102377_bib0017","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2024.102377_bib0018","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-4354","article-title":"Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention","volume":"9","author":"Tacke","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clinre.2024.102377_bib0019","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"Brennan","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2024.102377_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11901-018-0423-9","article-title":"The Clinical and Economic Burden of Nonalcoholic Steatohepatitis","volume":"17","author":"Lam","year":"2018","journal-title":"Curr Hepatol Reports"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T02:12:30Z","timestamp":1722996750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2210740124000986"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102377","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102377"}}